Accendra Health stock reports a USD 89.1 million Q2 loss

Published on 10/05/2026 at 16:31 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Accendra Health stock was trading at USD 0.51 on October 5, 2026, while Q2 revenue fell 10.1 percent year over year. Full-year revenue guidance stands at USD 2.45 billion to USD 2.55 billion.

ACH, US6907321029, Illustration mit AI erstellt.

Accendra Health (ISIN US6907321029) stock was trading at USD 0.51 on the NYSE at 10:26 a.m. ET on October 5, 2026, while the company reported a USD 89.1 million GAAP loss for the second quarter. Stock Titan said the Q2 filing dated August 10, 2026, also showed lower revenue and continued balance-sheet pressure.

Revenue falls to USD 613.2 million

Second-quarter net revenue came in at USD 613.2 million, down from USD 681.9 million a year earlier. That is a 10.1 percent year-over-year decline, giving the revenue line a sharper signal than the small daily stock move.

Stock Titan reported adjusted net loss of USD 14.3 million, compared with adjusted income of USD 20.5 million in the year-earlier period. Adjusted EBITDA fell to USD 60.1 million from USD 96.6 million, while free cash flow changed from positive USD 15.2 million to negative USD 25.1 million.

Debt reduction meets cash strain

Accendra Health reduced outstanding debt by USD 385 million during the quarter and extended its weighted average debt maturity from 2.7 years to 5.5 years. Cash and cash equivalents stood at USD 7.7 million on June 30, 2026, according to Stock Titan.

For full-year 2026, management reaffirmed revenue guidance of USD 2.45 billion to USD 2.55 billion and adjusted EBITDA guidance of USD 300 million to USD 320 million. The combination of lower quarterly revenue, negative adjusted earnings and limited cash makes execution against that range the central operating issue for the stock.

Consensus target remains above market price

Accendra Health has a consensus rating of Hold from five analysts, with an average price target of USD 1.51, according to Stock Analysis. Against the USD 0.51 NYSE price on October 5, 2026, that target lies 196.1 percent above the market price.

ACH market value stays below USD 40 million

Accendra Health was trading at USD 0.51 on the NYSE at 10:26 a.m. ET on October 5, 2026, up 1.78 percent from the prior close. Its market capitalization was USD 39.4 million, while the 52-week range stood at USD 0.50 to USD 5.60.